Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer Therapy
Studies from Brigham and Women's Hospital describe new findings in breast cancer therapy
December 25th, 2008
A report, 'VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapy,' is newly published data in Clinical Cancer Research. "Anti-vascular endothelial growth factor therapy (VEGF) is an important new treatment modality in oncology. We sought to determine the efficacy and safety of the humanized monoclonal anti-VEGF antibody, bevacizumab, and vinorelbine as treatment for refractory breast cancer and to explore the role of plasma VEGF as a predictor of treatment outcome," investigators in the United States report. "Eligible patients had received one or two prior chemotherapy regimens...
Source: Women's Health Weekly (2008-12-25)
|
